SIG
SAGE

Senator Investment Group’s Sage Therapeutics SAGE Stock Holding History

Senator Investment Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-150,000
Closed -$27.5M – 57
2019
Q2 		$27.5M Sell
150,000
-75,000
-33% -$12.8M 0.5% 45
2019
Q1 		$35.8M Buy
+225,000
New +$32.6M 0.81% 36

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Senator Investment Group's SAGE Position: Q3 2019 in Review

Senator Investment Group sold out of Sage Therapeutics (SAGE) in Q3 2019, closing a stake of 150,000 shares — an estimated $27.5M sold.

Senator Investment Group first reported a position in SAGE in Q1 2019 and held it in 2 quarters. The position peaked at $35.8M in Q1 2019. 284 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

  • Senator Investment Group reported no remaining Sage Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Senator Investment Group sold 150,000 Sage Therapeutics shares in Q3 2019, an estimated $27.5M.
  • Senator Investment Group first reported a position in Sage Therapeutics in Q1 2019 and held it in 2 quarters.
  • Senator Investment Group's Sage Therapeutics position peaked at $35.8M in Q1 2019.
  • 284 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Senator Investment Group's 13F filing for Q3 2019, filed 13 Nov 2019.